Connect Biopharma (CNTB) Competitors $1.98 +0.16 (+8.79%) Closing price 03:59 PM EasternExtended Trading$2.00 +0.02 (+1.26%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. LYEL, NMRA, FHTX, ALLO, JBIO, IMRX, LRMR, IMAB, HUMA, and VORShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Lyell Immunopharma (LYEL), Neumora Therapeutics (NMRA), Foghorn Therapeutics (FHTX), Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Immuneering (IMRX), Larimar Therapeutics (LRMR), I-Mab (IMAB), Humacyte (HUMA), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Its Competitors Lyell Immunopharma Neumora Therapeutics Foghorn Therapeutics Allogene Therapeutics Jade Biosciences Immuneering Larimar Therapeutics I-Mab Humacyte Vor Biopharma Lyell Immunopharma (NASDAQ:LYEL) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Which has more volatility & risk, LYEL or CNTB? Lyell Immunopharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500. Which has stronger valuation and earnings, LYEL or CNTB? Connect Biopharma has higher revenue and earnings than Lyell Immunopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$60K6,041.86-$342.99M-$24.29-0.78Connect Biopharma$26.03M4.24-$15.63MN/AN/A Is LYEL or CNTB more profitable? Connect Biopharma has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -552,328.31%. Connect Biopharma's return on equity of 0.00% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-552,328.31% -85.58% -68.85% Connect Biopharma N/A N/A N/A Do institutionals and insiders hold more shares of LYEL or CNTB? 66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 22.3% of Lyell Immunopharma shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate LYEL or CNTB? Lyell Immunopharma currently has a consensus target price of $15.00, suggesting a potential downside of 20.51%. Connect Biopharma has a consensus target price of $7.00, suggesting a potential upside of 253.54%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Does the media prefer LYEL or CNTB? In the previous week, Lyell Immunopharma and Lyell Immunopharma both had 3 articles in the media. Lyell Immunopharma's average media sentiment score of 1.61 beat Connect Biopharma's score of 1.28 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Connect Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryConnect Biopharma beats Lyell Immunopharma on 10 of the 14 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.33M$12.26B$9.05B$10.60BDividend YieldN/A2.28%5.69%4.71%P/E RatioN/A21.5785.8527.35Price / Sales4.24275.71535.75201.60Price / CashN/A47.1237.9261.55Price / Book1.1910.4213.056.78Net Income-$15.63M-$52.40M$3.30B$275.79M7 Day Performance42.45%6.37%4.79%2.63%1 Month Performance12.50%16.15%9.97%9.12%1 Year Performance46.67%33.92%85.15%35.86% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.6058 of 5 stars$1.98+8.8%$7.00+253.5%+42.2%$110.33M$26.03M0.00110Analyst ForecastHigh Trading VolumeLYELLyell Immunopharma1.609 of 5 stars$14.97+16.7%$15.00+0.2%-19.2%$287.57M$60K-0.62270News CoveragePositive NewsAnalyst ForecastNMRANeumora Therapeutics2.4126 of 5 stars$1.76+1.1%$7.14+305.8%-86.8%$285.03MN/A-1.12108Analyst ForecastFHTXFoghorn Therapeutics2.0829 of 5 stars$5.01+3.1%$11.00+119.6%-40.8%$283.22M$22.60M-4.21120News CoverageAnalyst ForecastALLOAllogene Therapeutics2.7345 of 5 stars$1.27+1.6%$8.44+564.9%-46.4%$281.79M$20K-1.14310Analyst ForecastJBIOJade Biosciences3.014 of 5 stars$8.62+1.7%$16.00+85.6%N/A$281.27MN/A-0.2820News CoverageAnalyst ForecastGap UpIMRXImmuneering3.9003 of 5 stars$6.75-16.5%$17.75+163.0%+172.0%$280.60M$320K-3.5760Analyst ForecastShort Interest ↑High Trading VolumeLRMRLarimar Therapeutics2.7908 of 5 stars$3.38-33.6%$18.43+445.2%-32.0%$279.80MN/A-2.1730News CoverageAnalyst ForecastHigh Trading VolumeIMABI-Mab2.8624 of 5 stars$3.42-1.7%$7.00+104.7%+272.8%$279.28M$3.89M0.00380Analyst ForecastGap UpHUMAHumacyte2.8282 of 5 stars$1.73flat$9.29+436.7%-69.5%$273.98M$1.57M-3.84150Analyst ForecastOptions VolumeGap DownVORVor BiopharmaN/A$39.89+18.6%$113.83+185.4%N/A$273.41MN/A-24.18140 Related Companies and Tools Related Companies LYEL Competitors NMRA Competitors FHTX Competitors ALLO Competitors JBIO Competitors IMRX Competitors LRMR Competitors IMAB Competitors HUMA Competitors VOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
